First-Line Antiseizure Medication Recommendations by Seizure Type
For adults with new-onset focal (partial) seizures, lamotrigine or levetiracetam should be first-line therapy, with carbamazepine as an alternative if neither is contraindicated 1, 2, 3. For generalized tonic-clonic seizures, sodium valproate remains the most effective first-line agent, though lamotrigine or levetiracetam are appropriate alternatives, particularly in women of childbearing potential 2.
Focal (Partial) Onset Seizures
Primary Recommendations
The evidence strongly supports a tiered approach for focal epilepsy:
First-tier options:
- Lamotrigine - Level B evidence for efficacy in new-onset focal epilepsy 3. High-quality network meta-analysis demonstrates lamotrigine performs better than most alternatives for treatment retention 2
- Levetiracetam - Level C evidence for new-onset focal epilepsy 3, but notably performed statistically better than both carbamazepine and lamotrigine for time to treatment withdrawal in network meta-analysis 2
- Carbamazepine - Traditional first-line agent with robust efficacy data, though tolerability may be inferior to newer agents 2
Second-tier options:
- Oxcarbazepine - Similar efficacy to carbamazepine with potentially better tolerability 4
- Zonisamide - Level C evidence for new-onset focal epilepsy 3
- Topiramate - Effective but cognitive side effects limit first-line use 1
Age-Specific Considerations
For patients ≥60 years old with new-onset focal epilepsy:
- Lamotrigine should be considered (Level B) 3
- Gabapentin may be considered (Level C) 3
- Avoid enzyme-inducing agents (carbamazepine, phenytoin) due to drug interactions and effects on bone health and cardiovascular risk 4
Avoid as First-Line
- Phenobarbitone - Consistently performed worse than other treatments for treatment retention despite good seizure control 2
- Gabapentin - Inferior to other options for treatment retention 2
Generalized Onset Seizures
Generalized Tonic-Clonic Seizures (with or without other generalized seizure types)
First-line:
- Sodium valproate - Performed significantly better than carbamazepine, topiramate, and phenobarbitone for treatment retention 2
Important alternatives:
- Lamotrigine - Suitable alternative, particularly for women of childbearing potential given valproate's teratogenicity 2
- Levetiracetam - Appropriate alternative to valproate, especially when valproate is contraindicated 2
Absence Seizures (Childhood Absence Epilepsy)
First-line:
- Ethosuximide or valproic acid should be considered before lamotrigine (Level B) 3
- Lamotrigine is third-line for absence seizures specifically
Juvenile Myoclonic Epilepsy
The evidence review notes insufficient data on efficacy of second- and third-generation AEDs for juvenile myoclonic epilepsy 3. Traditional guidance supports valproate as first-line, with levetiracetam and lamotrigine as alternatives.
Critical Decision-Making Algorithm
Step 1: Classify seizure type
- Focal → Proceed to Step 2A
- Generalized → Proceed to Step 2B
Step 2A: Focal Seizures - Select based on patient factors
- Standard adult (<60 years): Lamotrigine or levetiracetam
- Older adult (≥60 years): Lamotrigine preferred
- Psychiatric comorbidity: Avoid levetiracetam; use lamotrigine or carbamazepine
- Cardiac disease or polypharmacy: Avoid carbamazepine/phenytoin; use levetiracetam or lamotrigine
- Rapid titration needed: Levetiracetam (can reach therapeutic dose in days vs. weeks for lamotrigine)
Step 2B: Generalized Seizures - Select based on patient factors
- Male or non-childbearing potential: Sodium valproate
- Female of childbearing potential: Lamotrigine or levetiracetam (valproate contraindicated due to teratogenicity)
- Absence seizures specifically: Ethosuximide or valproate before lamotrigine
- Psychiatric comorbidity: Valproate or lamotrigine (avoid levetiracetam)
Common Pitfalls to Avoid
Delaying treatment initiation: Data shows 36.6% of patients wait ≥1 day for first prescription, and average time to regimen change exceeds 300 days 5. Initiate treatment promptly after diagnosis.
Using phenytoin or phenobarbitone as first-line: Despite good seizure control, these agents have poor treatment retention due to tolerability and drug interactions 2.
Prescribing valproate to women of childbearing potential: Teratogenicity risk mandates alternative agents unless no other option exists 2.
Ignoring comorbidities: Enzyme-inducing AEDs (carbamazepine, phenytoin) worsen cardiovascular disease, accelerate osteoporosis, and cause problematic drug interactions 4.
Inadequate titration of lamotrigine: Requires slow titration (weeks) to avoid serious rash; not appropriate when rapid seizure control is essential.
Evidence Quality Notes
The recommendations are based primarily on high-quality evidence from network meta-analysis of individual participant data from 36 trials involving 12,391 participants 2, supported by American Academy of Neurology/American Epilepsy Society guidelines 1, 3. The 2004 guideline 1 established efficacy of newer AEDs for refractory epilepsy, while the 2018 update 3 specifically addressed new-onset epilepsy. The Cochrane network meta-analysis 2 provides the most robust comparative effectiveness data available, though it notes that remission rates are similar across agents—the key differentiator is treatment retention (tolerability).
Critical limitation: Most evidence compares efficacy for seizure control, which is similar across agents. The primary distinguishing factor is tolerability and treatment retention, making patient-specific factors paramount in selection 2.